Tom Schaad

A selection of Mr. Schaad’s recent representations include:

Capital Markets Transactions

• The underwriters in Royalty Pharma plc’s $2.5 billion initial public offering and $728 million follow-on public offering
• The initial purchasers in Royalty Pharma plc’s $6 billion senior unsecured notes offering
• Morgan Stanley, Goldman Sachs & Co. LLC and other underwriters in Repare Therapeutics Inc.’s $253 million initial public offering
• Goldman Sachs & Co. LLC and other underwriters in Taysha Gene Therapies, Inc.’s $181 million initial public offering
• Achilles Therapeutics plc in its $175 million initial public offering
• Goldman Sachs & Co. LLC as lead underwriter DBV Technologies’ $143 million and $153 million follow-on public offerings
• Goldman Sachs & Co. LLC, Morgan Stanley and other underwriters in Pandion Therapeutics, Inc.’s $135 million initial public offering
• Goldman Sachs & Co. LLC and other underwriters in Ambrx Biopharma Inc.’s $126 million initial public offering
• Goldman Sachs & Co. LLC and other underwriters in Valneva SE’s $107 million initial public offering 
• HOOKIPA Pharma, Inc. in its $84 million initial public offering
• BELLUS Health Inc. in its $40 million follow-on public offering

Other Corporate Transactions

• Spark Therapeutics, Inc. in its $4.8 billion sale to Roche
• Normandy Real Estate Management, LLC, in its $100 million sale to Columbia Property Trust, Inc.